| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c17309f1bff06d9bebcd55b71c9d2fa4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y201-03003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1018 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-221
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0033 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-221
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2021-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3ab539718dcd4b64bae0aa8e9cd405a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28a358ff98c6fc237157c4c5428997f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91bbba0e58e66a11e10b817db3222701
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c778757c866c1f0a415652fd065d370
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_066bc4559973160b33c768257a9a8d90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fa01a4f73b0a828cfa4acd7022804be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b46eca710015939ed9ab926cc7bb9ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8e7d49bae9dbe9f06fbd133e692802c |
| publicationDate |
2021-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021284974-A1 |
| titleOfInvention |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| abstract |
The present disclosure describes compositions and methods for treating ornithine transcarbamylase (OTC) deficiency. The compositions include a lipid formulation and messenger RNA (mRNA) encoding an OTC enzyme. The lipid formulations can comprise an ionizable cationic lipid in a lipid nanoparticle encapsulating the mRNA. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116087165-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021290756-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11744887-B2 |
| priorityDate |
2020-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |